GlassScriptPhysician profile
Michael L Butera
NPI 1104925205
$17,943.80
in general payments reported to CMS, 2019-2025
22 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,478 · 2021: $499 · 2022: $694 · 2023: $213 · 2024: $66.87 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.79 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12,520.23 | 2019-2021 | |
| Allergan, INC. | $3,430.07 | 2019-2020 | |
| Glaxosmithkline, LLC. | $349.41 | 2019-2025 | Trelegy Ellipta, Nucala |
| Gilead Sciences, INC. | $255.36 | 2021-2022 | |
| Insmed, INC. | $251.61 | 2019-2025 | Brinsupri, Arikayce |
| Astellas Pharma US INC | $205.69 | 2022 | |
| Paratek Pharmaceuticals, INC. | $187.11 | 2020-2024 | Nuzyra |
| Genzyme Corporation | $104.51 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.04 | 2020-2023 | Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $99.91 | 2019-2021 | |
| Pfizer INC. | $90.41 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $50.58 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.48 | 2022 | |
| Sanofi Pasteur INC. | $45.55 | 2019-2021 | |
| Shionogi INC | $37.98 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30.74 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.05 | 2022 | |
| Baxter Healthcare | $25.91 | 2023 | Hillrom - Life 2000 Ventilation System |
| Melinta Therapeutics, LLC | $20.92 | 2023 | Orbactiv, Kimyrsa, Vabomere |
| Aimmune Therapeutics, INC. | $20.68 | 2025 | Vowst |
| Mylan Specialty L.P. | $20.01 | 2019 | |
| Philips North America LLC | $16.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Butera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.